Best Clinical Genomics Companies in New York, United States
The 55 best Clinical Genomics companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: C2i Genomics.
Ranked: Best Clinical Genomics companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | C2i Genomics Provider of liquid biopsy for post cancer surgery monitoring | $112M | 63 mo ago | 64 | 2019 | Ezra Sofer Co-Founder | Acquired | — | — |
| 2 | BioArray Solutions Beadchip for biomolecular analysis | $57M | 229 mo ago | 28 | 2001 | Jeffrey Binder CEO | Acquired | 288 patents Multiplexed nucleic‑acid detection and typing using micro‑particle array platforms | — |
| 3 | Provista Diagnostics Molecular oncology diagnostics company | $42M | 98 mo ago | 2 | 2007 | — | Acquired | 22 patents Cancer biomarker diagnostics for early detection of breast and ovarian cancers | — |
| 4 | Phosphorus Provider of next-generation diagnostics and tools for clinicians and researchers | $31M | 71 mo ago | 28 | 2016 | — | Deadpooled | — | — |
| 5 | Celmatix Pioneering ovarian health therapeutics for women's unique biological needs | $25M | 102 mo ago | 27 27 → 15 (-44%) | 2009 | Piraye Beim Founder and CEO | Series C | 136 patents FSH receptor modulators for fertility and peripheral melatonin receptor agonist delivery | — |
| 6 | AcuamarkDx Provider of non-invasive screening test for early detection of cancer | $20M | 25 mo ago | 6 | 2013 | Bernard Peperstraete Cofounder & CEO | Series A | — | — |
| 7 | Genoplan Developer of genetic test kits for health analysis | $20M | 94 mo ago | 16 | 2014 | — | Series B | 11 patents AI-based polygenic risk scoring and disease risk prediction using deep learning models | — |
| 8 | Nucleus Genomics Provider of genetic testing kits for rare variant analysis | $18M | 17 mo ago | 9 | 2021 | Kian Sadeghi Founder & CEO | Series A | — | 1 partnership |
| 9 | CDx Diagnostics Provider of AI-based platform to detect precancerous tissues | $16M | 73 mo ago | 146 146 → 119 (-18%) | 1997 | Mark Rutenberg Founder | Acquired | — | — |
| 10 | Jan Biotech Provider of diagnostic assays for the detection of infectious diseases 10Funding top 42%Talent bottom 45%Tech bottom 34%Global bottom 29% All 5 signals ▾Fundingtop 42% Talentbottom 45% Techbottom 34% Globalbottom 29% Marketbottom 14% Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $13M | 10 mo ago | 6 | 2014 | Jennifer Nichols President/Co-Founder | Funding Raised | — | — |
| 11 | Recombine Genetic testing services | $12M | 120 mo ago | 79 | 2011 | — | Acquired | — | — |
| 12 | OmniSeq Labcorp Oncology: Advancing cancer care through diagnostics, research, and precision medicine | $9M | 84 mo ago | 57 | 2015 | — | Series B | 25 patents AI-driven cancer genomics analytics for biomarkers, ancestry inference, and therapy selection | — |
| 13 | Aptamatrix Developer of next generation technology based diagnostic tools | $9M | 15 mo ago | 6 | 2003 | Philip Borer Co-Founder & President | Funding Raised | — | — |
| 14 | KellBenx Non-invasive prenatal diagnosis for specific genetic and other heritable disorders. | $8M | 81 mo ago | 5 | 2010 | Hassan Bennani CEO | Deadpooled | 38 patents Prenatal diagnostics: isolating and detecting fetal nucleated red blood cells using antibodies and filtration. | — |
| 15 | Population Bio Developer of targeted therapies and companion diagnostics for multiple diseases | $5M | 129 mo ago | — | 2006 | Peggy Eis Co-Founder and Chief Technology Officer | Series A | — | — |
| 16 | Vitatex Technology platform for capturing circulating tumor cells | $4M | 201 mo ago | — | 2002 | — | Acquired | 7 patents Liquid biopsy technologies for detecting circulating tumor and endothelial cells in blood. | — |
| 17 | Summit Biomedical Imaging Developer of diagnostic solutions for the early detection of cancer diseases | $4M | 16 mo ago | 3 | 2016 | Thomas Reiner Co-Founder & Scientific Advisor | Funding Raised | — | — |
| 18 | Episteme Prognostics Developer of precision therapeutics for pancreatic cancer | $4M | 37 mo ago | 2 | 2021 | Surajit Dhara Founder & CEO | Series A | 6 patents Epigenomic profiling of chromatin accessibility using qPCR‑based array assays | — |
| 19 | Isabl Developer of a medical diagnosis platform to analyze genome of cancer patients | $3M | 39 mo ago | 5 | 2020 | Juan Medina Co-Founder and CTO | Seed | — | — |
| 20 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 5 mo ago | 107 | 2014 | — | Public | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 21 | Thermal Gradient Provider of PCR-based diagnostic tools | $614K | 113 mo ago | 4 | 2004 | Bob Juncosa CEO | Deadpooled | 9 patents PCR thermal cyclers for nucleic acid amplification | — |
| 22 | CymoGen Dx Developer of genomic-based reagents and fluorescent in-situ hybridization probes | $350K | 192 mo ago | — | 2010 | Andrew Rogal Ex-President & CEO | Acquired | — | — |
| 23 | Girihlet Developer of a platform targeting the immune system and mitochondria to understand and fight disease | $250K | 114 mo ago | 2 | 2014 | — | Seed | 4 patents TCR/BCR chain pairing analysis and pure mitochondrial DNA isolation technologies. | — |
| 24 | Genomic Expression Provider of pharmacogenomic solutions for cancer | $200K | 67 mo ago | 12 | 2009 | — | Seed | — | — |
| 25 | Lifenome Provider of an AI based genomics-driven precision health and wellbeing solution | $100K | 60 mo ago | 26 | 2016 | — | Funding Raised | 7 patents Patents concentrated in computing, sensing & instrumentation | — |
| 26 | AccuTheranostics Provider of personalized chemotherapy test for an individual patient | $50K | 118 mo ago | 4 | 2012 | Arvind Thakur Co-Founder | Funding Raised | — | — |
| 27 | Signifikance Online gaming platform offering diverse slot games with guaranteed max wins | $20K | 137 mo ago | — | 2014 | Vidit S Co-Founder | Deadpooled | — | — |
| 28 | Dante Labs Provider of whole-genome sequencing analysis for health and wellness | — | 38 mo ago | 156 | 2016 | Andrea Riposati Co-Founder & CEO | Seed | — | — |
Top 12 Clinical Genomics companies in New York
#1
Funding Raised · Ithaca, New York · founded 2014 · 6 employees$13.4Mraised▾
Provider of diagnostic assays for the detection of infectious diseases. The company offers novel molecular in vitro assays for clinical diagnosis and quantification of latent infections such as HIV-1, as well as detection of aggressive cancer (ex., prostate) and cancer treatment monitoring.
- Aug 2025Grant (prize money)$3.3M
- Feb 2025Grant (prize money)$300K
- Feb 2025Grant (prize money)$3.3M
- Sep 2023Grant (prize money)$300K
#2
Public · New York City, New York · founded 2014 · 107 employees$845Kraised▾
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include "CarpX" a minimally invasive device to treat carpal tunnel syndrome, "PortIO" a novel, implantable, intraosseous vascular access device, and "DisappEAR" antimicrobial resorbable ear tubes, and many more.
- Feb 2026Post IPO$30M
- Feb 2025Post IPO$2.4M
- Jan 2025Post IPO$2.7M
- Sep 2024Grant (prize money)$892.1K
#3
Funding Raised · Syracuse, New York · founded 2003 · 6 employees$8.6Mraised▾
AptaMatrix is a biotechnology company focused on developing next-generation technology (High Throughput Screening of Aptamers (HTSA)) based on new tools to accelerate the aptamer's discovery. The company is developing an aptamer-based platform "AlloSwitch" sensor technology that can facilitate drug discovery and rapid detection of chemical and biological analytes. The company claims that using their AptaMatirx's proprietary workflow, the time required for aptamer discovery can be reduced to 2 weeks which can be further reduced to 3 days in the future. In addition, the company provides consulting and technical support to both academic and commercial deep-sequencing projects.
- Apr 2025Grant (prize money)$2M
- Sep 2020Grant (prize money)$2M
- Jul 2016Grant (prize money)$176.8K
- Sep 2010Grant (prize money)$1.1M
#4
Series A · Manhattan, New York · founded 2021 · 9 employees$18Mraised▾
Provider of genetic testing kits for rare variant analysis. The company offers direct to consumer genetic testing platform that provides genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).
- Jan 2025Series A$14M
- Jul 2022Series A$14M
- Dec 2021Seed$3.5M
#5
Funding Raised · New York City, New York · founded 2016 · 3 employees$4.1Mraised▾
Developer of diagnostic solutions for the early detection of cancer diseases. The company has developed a fluorescent small molecule, PARPi-FL by using propitiatory technology that helps to detect early stage of PARP1, which is common in certain cancers. It also helps in diagnosing In vivo oral cancer, Ex vivo cervical cancer, Ex vivo esophageal cancer, Ex vivo breast cancer, and more.
- Mar 2025Grant (prize money)$1.8M
- Sep 2020Grant (prize money)$1.8M
- Mar 2019Grant (prize money)$300K
- Sep 2018Grant (prize money)$299.9K
#6
Series A · New York City, New York · founded 2013 · 6 employees$20Mraised▾
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
- May 2024Series A$4.9M
- Jul 2022Series A$11.3M
- Sep 2019Seed$2.3M
- Nov 2016Seed$1.5M
#7
Acquired · New York City, New York · founded 2019 · 64 employees$112Mraised▾
Provider of liquid biopsy for post-cancer surgery monitoring. It provides a tool for cancer tumor monitoring. It identifies changes in genetic patterns across the entire tumor. Based on advanced bioinformatics and AI, it compares thousands of data points obtained from periodic liquid biopsy blood tests of a patient to sequenced tumor tissue and whole-genome analysis.
- Mar 2021Series B$100M
- May 2020Series A$12M
#8
Acquired · New York City, New York · founded 2007 · 2 employees$41.8Mraised▾
Provista Diagnostics develops blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. Near term development and commercialization efforts focus on women’s cancers such as breast and ovarian cancer. Provista’s proprietary ProteoMark Technology combines multiple serum protein biomarkers and tumor-associated autoantibodies, with patient clinical data, to accurately diagnose women’s cancers.
- May 2018Series C$2.2M
- May 2018Conventional Debt—
- Jul 2017Series C$2.3M
- Jul 2017Conventional Debt—
#9
Acquired · New York City, New York · founded 2001 · 28 employees$56.8Mraised▾
Bioarray solutions focuses on developing bead-based assays for nucleic acid and protein analysis.It has also developed products for genetic diagnostics and infectious disease agent profiling, and, FDA clearance for an autoantibody profiling ("ENA") BeadChip™ assay on its Array Imaging System. Its BeadChip(TM) system deploys planar arrays of proprietary encoded microparticles to perform rapid and reliable molecular analysis of nucleic acids and proteins.The company was acquired by Immucor in March, 2008.
- 2007Series E$25M
- 2006Series D$20M
- Jun 2005Series B$1.3M
- Jan 2005Series B$10.5M
#10
Deadpooled · New York City, New York · founded 2016 · 28 employees$31.4Mraised▾
Provider of next-generation diagnostics and tools for clinicians and researchers. It has two diagnostic products including HeartMap for hereditary sudden cardiac disorders and LipidMap for hereditary high cholesterol. In addition, it has a software solution that enables laboratories to use NGS tools in their practice. The software suite contains systems for laboratory management, scalable data storage, reporting, and patient management modules, an NGS variant database, and genetic counseling tools.
- Aug 2020Series B$8M
- Jul 2018Series B$13.4M
- Jul 2018Conventional Debt—
- Jul 2016Series A$10M
#11
Series C · New York City, New York · founded 2009 · 27 employees$24.9Mraised▾
Pioneering ovarian health therapeutics for women's unique biological needs. This preclinical-stage biotech company is focused on groundbreaking therapies for women's health, addressing conditions like endometriosis, premature menopause, and polycystic ovary syndrome (PCOS). They are developing a pipeline of innovative drug programs, including an AMHR2 agonist program focused on ovarian aging, an oral FSH receptor agonist for infertility, and an immunotherapy for endometriosis. Their approach centers on new biology and novel approaches to solve long-standing problems in women's health, paving the way for a new era in women's therapeutics. They aim to create transformative drugs that address the unmet needs of modern women, allowing them to live longer, healthier lives by targeting immune function, glucose metabolism, bone health, mental health, sleep, pregnancy, and sexual function.
- Dec 2017Series C$4.5M
- Mar 2016Series C$4.8M
- Aug 2015Series C$3.8M
- Dec 2014Series C$5.5M
#12
Series A · New York City, New York · founded 2021 · 2 employees$4.1Mraised▾
Developer of precision therapeutics for pancreatic cancer. It offers epigenetic therapy that can reactivate the expression of the regulatory genes and make the tumors responsive to chemotherapy.
- May 2023Series A$4.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Washington University ST Louis; annual filings 13→55.
- Detect42
- UNIV Leland Stanford Junior33
- Washington University ST Louis20
- UNIV California19
- Texas A & M UNIV SYS19
- Nuclein19
- Tempus LABS18
- New England Biolabs18
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.